title: Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
authors.affiliation: Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15213.
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: S
authors.initials: S
authors.lastname: Todo
authors.forename: A
authors.initials: A
authors.lastname: Tzakis
authors.forename: A
authors.initials: A
authors.lastname: Demetris
authors.forename: A
authors.initials: A
authors.lastname: Jain
authors.forename: K
authors.initials: K
authors.lastname: Abu-Elmaged
authors.forename: M
authors.initials: M
authors.lastname: Alessiani
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D016559:Tacrolimus; D014184:Transplantation, Homologous
chemical_list: D000900:Anti-Bacterial Agents; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D016559:Tacrolimus